[目的]探讨尿多酸肽对晚期非小细胞肺癌患者的细胞免疫功能的影响。[方法]45例晚期非小细胞肺癌患者。单纯化疗组26例,采用NP(NVB+DDP)方案化疗。尿多酸肽联合化疗组19例,NP方案化疗联合应用尿多酸肽静脉滴注4～8周。两组均于化疗前及化疗2周期后,采用流式细胞仪检测T细胞亚群。[结果]单纯化疗组化疗前、后CD3+、CD4+、CD8+以及CD4+/CD8+差异显著(P<0.05),化疗后免疫功能明显下降。尿多酸肽联合化疗组治疗前、后CD3+、CD4+/CD8+无显著性差异(P>0.05),免疫功能无明显变化。两组化疗后CD3+、CD4+以及CD4+/CD8+比较差异显著(P<0.01),联合尿多酸肽组化疗后免疫功能明显高于单纯化疗组。[结论]晚期非小细胞肺癌患者普遍存在免疫功能紊乱和低下,化疗使细胞免疫功能进一步降低,尿多酸肽能促进化疗患者细胞免疫功能的恢复。 [Objective] To investigate the effect of uroacitides on cellular immune function in patients with advanced non-small cell lung cancer. [Method] 45 patients with advanced non-small cell lung cancer. Simple chemotherapy group of 26 patients, using NP (NVB + DDP) regimen chemotherapy. Ninety-nine patients were treated with uroacitides combined with chemotherapy and NP chemotherapy combined with uroacitides for four to eight weeks. Both groups before chemotherapy and 2 cycles of chemotherapy, the detection of T cell subsets by flow cytometry. [Results] The levels of CD3 +, CD4 +, CD8 + and CD4 + / CD8 + in the chemotherapy group were significantly different (P <0.05) before and after chemotherapy, and the immunologic function was significantly decreased after chemotherapy. There was no significant difference in CD3 +, CD4 + / CD8 + before and after treatment between uroacitides and chemotherapy group (P> 0.05), and immune function did not change significantly. There were significant differences in CD3 +, CD4 + and CD4 + / CD8 + between the two groups after chemotherapy (P <0.01). The immunologic function of the combination group was significantly higher than that of the chemotherapy alone group. [Conclusion] Immune dysfunction is generally low in patients with advanced non-small cell lung cancer. Chemotherapy can further decrease the cellular immune function. Urinary poly-acid peptide can promote the recovery of cellular immune function in patients with chemotherapy.